Yunnan Biovalley Pharmaceutical (BJ:833266)2025-01-24 11:20Financial Performance - The company's net profit attributable to shareholders is expected to be between -75.28 million and -61.60 million CNY, compared to -12.20 million CNY in the same period last year, representing a change of -517.06% to -404.87%[5] - The decline in revenue is primarily due to the dual impact of industry and centralized procurement policies, leading to price reductions for core products such as Lingzhan Shenmai Capsules and Lingzhan Xixin Injection[6] - The company has recognized a bad debt provision of 66.82 million CNY during the reporting period, compared to 43.69 million CNY in the previous period, with a cumulative bad debt provision of 200.46 million CNY[6] Audit and Reporting - The financial data presented is preliminary and has not been audited by an accounting firm, and the final figures will be disclosed in the company's 2024 annual report[7] Corporate Governance - The company is actively pursuing the resolution of fund occupation issues with its former controlling shareholder, Shenzhen Jinsanjiang Investment Co., Ltd., and its actual controller, Lin Yanhe[6]